Re‐assessing the late HIV diagnosis surveillance definition in the era of increased and frequent testing. Issue 11 (7th September 2022)

• Record Type: Journal Article
• Authors: Kirwan, Peter D.; Croxford, Sara; Aghaizu, Adamma; Murphy, Gary; Tosswill, Jennifer; Brown, Alison E.; Delpech, Valerie C.
• Other Names: Parczewski Milosz guestEditor.
• Is Part Of: HIV medicine. Volume 23:Issue 11(2022)
• Page Start: 1127
• Page End: 1142
• Publication Date: 2022-09-07
• Subjects: HIV -- HIV testing -- late diagnosis -- late presentation -- seroconversion; HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.13394
• Languages: English
• ISSNs: 1464-2662

Abstract

Abstract: Objectives: Late HIV diagnosis (CD4 <350 cells/mm 3 ) is a key public health metric. In an era of more frequent testing, the likelihood of HIV diagnosis occurring during seroconversion, when CD4 counts may dip below 350, is greater. We applied a correction, considering markers of recent infection, and re‐assessed 1‐year mortality following late diagnosis. Methods: We used national epidemiological and laboratory surveillance data from all people diagnosed with HIV in England, Wales, and Northern Ireland (EW&NI). Those with a baseline CD4 <350 were reclassified as 'not late' if they had evidence of recent infection (recency test and/or negative test within 24 months). A correction factor (CF) was the number reclassified divided by the number with a CD4 <350. Results: Of the 32 227 people diagnosed with HIV in EW&NI between 2011 and 2019 with a baseline CD4 (81% of total), 46% had a CD4 <350 (uncorrected late diagnosis rate): 34% of gay and bisexual men (GBM), 65% of heterosexual men, and 56% of heterosexual women. Accounting for recency test and/or prior negative tests gave a 'corrected' late diagnosis rate of 39% and corresponding CF of 14%. The CF increased from 10% to 18% during 2011–2015, then plateaued, and was larger among GBM (25%) than heterosexual men and women (6% and 7%, respectively). One‐year mortality among people diagnosed late was 329 per 10 000 after reclassification (an increase from 288/10 000). Conclusions: The case‐surveillance definition of late diagnosis increasingly overestimates late presentation, the extent of which differs by key populations. Adjustment of late diagnosis is recommended, particularly for frequent testers such as GBM.